The discovery of anti-infective compound usually starts with in vitro screening of test compounds followed by in vivo testing of potential drugs. If mammals are selected as the model for in vivo testing, there are limitations such as high cost, time-consuming and ethical now. To overcome these limitations, C. elegans can be used for initial screening of anti-infective compounds. Here, we offer a high-throughput anti-infective compounds screen service using the advanced automatic equipment to meet our customers' research needs in this area.
The nematode C. elegans, a live animal has been used in small molecule screening systems to identify anti-infective compounds with therapeutic potential. Due to the notable similarities between the nematode and higher vertebrates at molecular and cellular levels, it seems that C. elegans exhibit superior function over conventional antibiotics in the discovery of novel therapeutics for human infections.
Fig.1 Schematic diagram illustrating the possible outcomes of a Caenorhabditis elegans-based anti-infective screen. (Kong C, et al., 2016)
At CD BioSciences, we offer fully customized screening of anti-infective compounds using our C. elegans high-throughput screening platform. Anti-infective compound screening is performed by monitoring worm survival after exposing C. elegans to pathogens and compounds to be tested. Our services include but are not limited to:
Screening for Immunostimulatory Compounds
This is an emerging strategy to develop new anti-infective small molecules by selectively modulating host innate immunity. CD BioSciences utilizes C. elegans transgenic, GFP-based immune reporter strains in a high-throughput screening platform to help you perform primary screening of pairs of compound libraries for immunostimulatory molecules.
Screening for Anti-virulence Compounds
This method refers to the screening of anti-infective compounds with virulence factors that destroy pathogens. Biofilms play a key role in bacterial pathogenesis and are another important virulence factor. We can help you screen not only for anti-infective compounds that interfere with bacterial virulence factors, but also for anti-infective compounds that target biofilms.
Screening for Pathogen-targeting Compounds
Utilizing our excellent C. elegans high-throughput screening platform, we also offer screening services for anti-infective compounds by directly targeting pathogens. In addition, to complement our antibiotic discovery services, we deploy C. elegans-based pathogenesis assays to identify new antifungal therapies in our platform.
Culturing C. elegans: C. elegans is cultured on agar plates inoculated with E. coli (OP 50).
C. elegans exposed to pathogen.
Automated sorting of C. elegans into assay wells.
Automated addition of compound libraries into assay wells
Automated image analysis and data analysis
CD BioSciences is a dedicated provider of C. elegans model services. Here we provide anti-infective compounds screening service, involving immunostimulatory compounds, anti-virulence compounds and pathogen-targeting compounds. We are dedicated to accelerating the speed to achieve customers' research goals with high-quality. If you are interested in our service, please feel free to contact us for more information.